Derniers manuscrits de l'équipe
-
-
Anne-Laure Désage, Michaël Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid, et al.. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature. Cancer Treatment Reviews, 2024, 129, ⟨10.1016/j.ctrv.2024.102805⟩. ⟨hal-04728403⟩
-
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, et al.. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences, 2024, 25, ⟨10.3390/ijms25073992⟩. ⟨hal-04728435⟩
-
Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, et al.. Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. Biomedicines, 2024, 12, ⟨10.3390/biomedicines12030704⟩. ⟨hal-04728446⟩
-
-
Manon Gouez, Amélie Rébillard, Amandine Thomas, Sabine Beaumel, Eva-Laure Matera, et al.. Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice. Frontiers in Immunology, 2024, 15, pp.1368550. ⟨10.3389/fimmu.2024.1368550⟩. ⟨hal-04479752⟩